JUBILANT ORGANOSYS
ScienceActive

October 01, 2010

The Bombay Stock Exchange Ltd.
1st Floor, New Trading Ring
Rotunda Building,
Piroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai - 400 001
Fax : 022 – 22722041 / 61 / 37 / 39

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Bandra-Kurla Complex,
Bandra (E)
Mumbai - 400 051

Fax : 022 - 26598237 / 38, 26598347 / 48

Re: Tender Offer by an indirect, wholly-owned subsidiary of Jubilant Organosys Ltd. (the "Company")

Sir,


This is to inform you that an indirect wholly-owned subsidiary of the Company, Jubilant Life Sciences Holdings Inc., ("Jubilant Life Sciences Holdings"), effective as of September 30, 2010, is commencing a tender offer for all outstanding shares of common stock (collectively, "Shares") of Cadista Holdings Inc., ("Cadista"), not currently owned by Jubilant Life Sciences Holdings and Jubilant Pharma Pte. Ltd., Singapore, ("JPPL") another wholly owned subsidiary of the Company. The Company, through Jubilant Life Sciences Holdings and JPPL, currently holds approximately 82.4% of the outstanding shares of common stock of Cadista. Both Jubilant Life Sciences Holdings and Cadista have been formed under the laws of the State of Delaware of the United States of America, and the tender offer is being made in compliance with such laws.

The price being offered by Jubilant Life Sciences Holdings is US$ 0.30 per Share. The tender offer will commence on September 30, 2010 and is currently scheduled to expire at 5:00 P.M, New York City Time, on October 29, 2010. Jubilant Life Sciences Holdings may extend the current expiration date of the tender offer, otherwise amend its terms, or terminate the tender offer in its sole discretion.

The offer is subject to the condition that the majority of the outstanding Shares not owned by Jubilant Life Sciences Holdings or JPPL, immediately prior to the expiration of the tender offer, must be validly tendered. This "majority of the minority Shares condition" is not waivable. There are a number of other conditions to the consummation of the tender offer that are waivable by Jubilant Life Sciences Holdings, in its sole discretion.

Jubilant Organosys Ltd.
1-A, Sector16-A
Noida-201 301,UP,India
Ph. :+91 120 2516601-11
Fax :+91 120 2511007
web : www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Jyotiba Phuley Nagar - 244 223 (UP)



If the non-waivable majority of the minority Shares condition is satisfied, then Jubilant Life Sciences Holdings and JPPL will collectively own in excess of 90% of the outstanding Shares and will cause Cadista to promptly consummate a "short-form" merger under Delaware corporate law pursuant to which any remaining outstanding Shares not owned by Jubilant Life Sciences Holdings and JPPL will be converted into the right to receive cash equal to the tender offer price (subject to certain appraisal rights that such stockholders have under applicable Delaware law). This merger transaction will result in Jubilant Life Sciences Holdings owning 100% of the Shares of Cadista.

Based upon the current offer price of US$ 0.30 per Share, the total purchase price to be paid for all outstanding Shares of Cadista, not currently owned by Jubilant Life Sciences Holdings and JPPL, will be approximately US$ 6.2 Million. Such amount is subject to adjustment in the Company's sole discretion.

The Company does not believe the tender offer transaction is material to the Company's consolidated operations since Cadista's consolidated net revenues for its fiscal year ended March 31, 2010 were US$ 28.77 million as compared to the Company's consolidated net revenues of approximately US$ 796.90 million during this same period.

The tender offer being made by Jubilant Life Sciences Holdings is being extended directly to Cadista's shareholders by mailing tender offer materials that include, among other things, certain business, financial and other information that may be material to such minority shareholders in determining whether to accept the tender offer. Cadista is not required to publicly file periodic reports under applicable United States Securities Laws, and neither Cadista nor the Company or any of its affiliates are currently planning to issue any public press releases regarding the tender offer. In addition, the tender offer documents will be circulated solely to the minority shareholders and will not otherwise be publicly circulated or posted on the Company's website.

In case if you need any further clarification please contact the undersigned at e-mail lalit_jain@jubl.com or Phone No. +91 120 2516601-11

Yours faithfully,
For **JUBILANT ORGANOSYS LIMITED**

LALIT JAIN
COMPANY SECRETRAY